Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;10(1):2125-2127.
doi: 10.1080/22221751.2021.1996210.

Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern

Lei Yue  1 , Jian Zhou  1 , Yanan Zhou  1 , Xiaolei Yang  1 , Tianhong Xie  1 , Mengli Yang  1 , Hongling Zhao  1 , Yuan Zhao  1 , Ting Yang  1 , Hua Li  1 , Hong Xiang  1 , Jie Wang  1 , Shuaiyao Lu  1 , Hongqi Liu  1 , Hong Zhao  1 , Xingchen Wei  1 , Yuhao Zhang  1 , Zhongping Xie  1
Affiliations

Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern

Lei Yue et al. Emerg Microbes Infect. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern. (A–C) Enzyme-linked immunosorbent assay (ELISA) antibody against S protein, neutralizing antibody against original strain (GD108#), and the IFN-γ-specific T-cell responses against the S, N, M, and O antigens induced by a third booster dose of inactivated SARS-CoV-2 vaccine (n = 6). (D and E) Human neutralizing antibodies and positive rate against original strain (GD108#) and variants (alpha, beta, delta) induced by the inactivated SARS-CoV-2 vaccine 14 days after a third booster dose (n = 53). (F, G) Monkey neutralizing antibodies and positive rate against original strain (GD108#) and variants induced by the inactivated SARS-CoV-2 vaccine 14 days after a third booster dose (n = 12). The neutralizing antibody-positive judgment threshold is marked with a dotted line. (*p < 0.05; **p < 0.01; ***p < 0.001).
Figure 1.
Figure 1.
Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern. (A–C) Enzyme-linked immunosorbent assay (ELISA) antibody against S protein, neutralizing antibody against original strain (GD108#), and the IFN-γ-specific T-cell responses against the S, N, M, and O antigens induced by a third booster dose of inactivated SARS-CoV-2 vaccine (n = 6). (D and E) Human neutralizing antibodies and positive rate against original strain (GD108#) and variants (alpha, beta, delta) induced by the inactivated SARS-CoV-2 vaccine 14 days after a third booster dose (n = 53). (F, G) Monkey neutralizing antibodies and positive rate against original strain (GD108#) and variants induced by the inactivated SARS-CoV-2 vaccine 14 days after a third booster dose (n = 12). The neutralizing antibody-positive judgment threshold is marked with a dotted line. (*p < 0.05; **p < 0.01; ***p < 0.001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhu N, Zhang D, Wang W, et al. . A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–733. - PMC - PubMed
    1. Holshue ML, DeBolt C, Lindquist S, et al. . First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929–936. - PMC - PubMed
    1. Al Kaabi N, Zhang Y, Xia S, et al. . Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021 Jul 6;326(1):35–45. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416. - PMC - PubMed
    1. Ramasamy MN, Minassian AM, Ewer KJ, et al. . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979–1993. - PMC - PubMed

Publication types

Grants and funding

This work was supported by National Natural Science Foundation of China: [Grant Number 81800012]; Yunnnan Provincial Science and Technology Department: [Grant Number 202105AC160025]; Chinese Academy of Medical Sciences: [Grant Number 2020-I2M-CoV19-012]; Health Commission of Yunnan Province: [Grant Number H-2018061]; Kunming Science and Technology Bureau: [Grant Number 2020-1- H-021].